PDS Biotechnology Corporation宣布,其PDS01ADC在由国家癌症研究所(NCI)主导的转移性结直肠癌(MCRC)二期临床试验第一阶段的中期研究数据已正式发表。此次公布的数据显示积极的临床效果,为后续治疗方案的推进提供了重要依据。
PDS Biotechnology Corporation宣布,其PDS01ADC在由国家癌症研究所(NCI)主导的转移性结直肠癌(MCRC)二期临床试验第一阶段的中期研究数据已正式发表。此次公布的数据显示积极的临床效果,为后续治疗方案的推进提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.